Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 2/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.45 |
| ▸ | CDK4 | P11802 | 6/20 | 0.44 |
| ▸ | CCND1 | P24385 | 6/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | PARP1 | P09874 | 2/20 | 0.43 |
| ▸ | GUSB | P08236 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6775219 | 0.78 | CRHR1 (0.39) | KDM4EGUSB | |
| SCHEMBL6776982 | 0.76 | TYMS (0.45) | TYMSPIM1PIM2CDK4CCND1 | |
| SCHEMBL7041005 | 0.71 | HSD11B1 (0.45) | ALDH1A1HTTHPGD | |
| SCHEMBL16306349 | 0.69 | PARP1 (0.60) | TYMSPIM1PIM2CDK4CCND1 | |
| SCHEMBL16008205 | 0.68 | BRD4 (0.69) | — | |
| SCHEMBL6778080 | 0.68 | CRHR1 (0.61) | — | |
| SCHEMBL7046189 | 0.68 | HSD11B1 (0.47) | KDM4EALDH1A1HPGD | |
| SCHEMBL6777296 | 0.67 | CRHR1 (0.62) | — | |
| SCHEMBL16306345 | 0.67 | PARP1 (0.54) | TYMSPIM1PIM2CDK4CCND1 | |
| SCHEMBL16306347 | 0.67 | PARP1 (0.54) | TYMSPIM1PIM2CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6734185-B2 | Pyrrolo[3,4-d]pyrimidines as corticotropin releasing factor (CRF) antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-05-11 | — | — | US | disclosed |
| US-20030220333-A1 | Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists | BAKTHAVATCHALAM RAJAGOPAL (US) | 2003-11-27 | — | — | US | disclosed |
| US-6630476-B2 | For therapy of anxiety, depression, and other psychiatric, neurological disorders, immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-10-07 | — | — | US | disclosed |
| US-20020022632-A1 | Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022632-A1 | Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists | CRH, CRHR1, CRHR2 | TYMS 73/4885PIM1 3436/4885PIM2 4084/4885 |
| US-20030220333-A1 | Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists | CRH, CRHR1, CRHR2 | TYMS 63/4885PIM1 3618/4885PIM2 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.